The role of germline BRCA1 & BRCA2 mutations in familial pancreatic cancer: A systematic review and meta-analysis.

Edward Kurnia Setiawan LimijadiMuflihatul MunirohYan Wisnu PrajokoKevin Christian Tjandra Danendra Rakha Putra Respati

Published in: PloS one (2024)

Detecting the BRCA1/2 mutation gene offers numerous advantages, particularly in its correlation with FPC. For diagnostic and prognostic purposes, testing is strongly recommended for first-degree relatives, who face a significantly higher risk (2.26-10 times) of being affected. Additionally, FPC patients with identified BRCA1/2 mutations exhibit a more favorable prognosis compared to the non-mutated population. This is attributed to the availability of targeted BRCA1/2 therapy, which maximizes treatment outcomes.

Keyphrases

breast cancer risk
gene expression
copy number
genome wide
cancer therapy
dna damage
transcription factor